UCB SA
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| UCB.VI | 1530.HK | 1177.HK | 688177.SS | 9969.HK | 1801.HK | |
|---|---|---|---|---|---|---|
| Market cap | 41.01B | 35.39B | 96.13B | 7.37B | 22.21B | 158.26B |
| P/E (TTM) | 19.0 | 3.9 | 36.0 | — | 20.6 | 117.9 |
| Forward P/E | — | 10.5 | 16.9 | -26.2 | 59.4 | 35.8 |
| Price/book | 3.5 | 1.1 | 2.5 | 59.5 | 2.4 | 6.5 |
| Dividend yield | 0.68% | 1.70% | 2.59% | — | — | — |
| 1-year change | −15.00% | −46.66% | −25.00% | −33.37% | −10.20% | +2.58% |
| Today | +0.94% | −2.79% | +0.93% | −0.56% | +0.56% | +1.85% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All UCB.VI news ›United Community Banks, Inc. (UCB) Q3 2026 Earnings Call Transcript
United Community Banks, Inc. (UCB) Q3 2026 Earnings Call October 20, 2026 8:30 AM EDTCompany ParticipantsHerbert Harton - President, Chairman & CEOTom... United Community Banks, Inc. (UCB) Q3 2026 Earnings Call October 20, 2026 8:30 AM EDT…
United Community Banks (NYSE:UCB) Reports Sales Below Analyst Estimates In Q3 2026 Earnings
Regional banking company United Community Banks (NYSE:UCB) fell short of the market’s revenue expectations in Q3 2026, with sales falling 104% year on year to -$11.97 million. Its non-GAAP profit of $0.77 per share was in line with…
United Community Banks, Inc. Stock (UCB) - Quote NYSE
United Community Banks, Inc. is the financial holding company for United Community (the Bank). The Bank offers a full range of banking, mortgage and wealth management services. The Bank operates approximately 200 offices across Alabama,…
Earnings Flash (UCB) United Community Banks Posts Q3 Operating EPS $0.77, vs. FactSet Est of $0.77
... United Community Banks, Inc. Earnings Flash (UCB) United Community Banks Posts Q3 Operating EPS $0.77, vs. FactSet Est of $0.77 Published on 10/20/2026 at 07:21 am EDT
UCB announces U.S. FDA approval for ZILBRYSQ® (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis
The ZILBRYSQ autoinjector is designed to automatically deliver a pre-defined dose when activated against the skin.1,2 Prior to the autoinjector's approval, ZILBRYSQ was available as a self-administered prefilled syringe (PFS). Patients or…
UCB Launches ‘Wear It Out’ Campaign for People Living With HS, PsO and PsA: Here’s What to Know
The Dermatology Digest UCB Launches ‘Wear It Out’ Campaign for People Living With HS, PsO and PsA: Here’s What to Know Developed alongside patient advocates and artist Sophia Yeshi, the Wear It Out program showcases the everyday, often…
FDA green light for UCB and positive view from DB
Belgian biopharmaceutical group UCB has announced that the US FDA has approved a new administration option for Zilbrysq (zilucoplan), its treatment for generalized myasthenia gravis in adult patients with anti-acetylcholine receptor (AChR)…
UCB (UCB) Gets FDA OK for ZILBRYSQ Autoinjector; US Launch Expected Q1 2027
TradingView UCB (UCB) Gets FDA OK for ZILBRYSQ Autoinjector; US Launch Expected Q1 2027 UCB received U.S. FDA approval for a once-daily ZILBRYSQ (zilucoplan) autoinjector for AChR+ adult gMG, adding a self-admin option to the existing PFS.…
UCB holds RMG conclave to promote sustainable industry
The United Commercial Bank PLC (UCB) recently organised a business conclave with senior garment and textile industry representatives to promote export competitiveness, energy security and sustainability challenges facing the sector. The…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com4
-
tradingview.com4
-
thedailystar.net3
-
dazzlingdawn.com2
-
tbsnews.net2
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 42 articles, not a forecast.